Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories, Otsuka - LARVOL DELTA

Stress-Induced Cardiomyopathy Following Elective Lumbar Disc Nucleotomy: Multimodal Cardiac Evaluation With 2D-STE and D-SPECT in a Patient With Severe Cardiac Magnetic Resonance (CMR) Contraindication. (PubMed, Cureus) - "The patient received guideline-directed medical therapy consisting of sacubitril/valsartan, beta-blockers, mineralocorticoid receptor antagonists, and a sodium‑glucose cotransporter 2 (SGLT2) inhibitor...In this individual patient with CMR contraindications, combined 2D‑STE and D‑SPECT provided complementary supportive diagnostic information. Further studies are required to validate the general utility of this multimodal imaging approach."

Journal • Cardiomyopathy • Cardiovascular • Inflammation • Myocardial Infarction

Sex differences in leptin levels but not in the leptin response to sacubitril/valsartan in patients with heart failure with reduced ejection fraction. (PubMed, Front Cardiovasc Med) - "Sex influences baseline leptin concentrations, but not the response to ARNI therapy. Further prospective studies are needed to clarify the mechanisms and clinical significance of leptin changes during sacubitril/valsartan treatment."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • LEP

Cocktail Therapy Combining SGLT2 Inhibitor, Entresto, and Adipose-Derived Mesenchymal Stem Cells Prevents Abdominal Aortic Aneurysmal Complication Syndrome in Rodents. (PubMed, Acta Cardiol Sin) - "This study investigated whether triple combination therapy [dapagliflozin (DAPA) + sacubitril/valsartan (Entresto) + adipose-derived mesenchymal stem cells (ADMSCs)] offered additional benefits on preventing complication syndrome [defined as abdominal aortic aneurysm (AAA) dilatation, muscle layer destruction and inflammation] in rodents with AAA. The protein expressions of inflammation (tumor necrosis factor-alpha/interleukin (IL)-1 beta/IL-6/MMP2/MMP9)/fibrosis (transforming growth factor-beta/mothers against decapentaplegic homolog 3) markers displayed an identical pattern, whereas the protein expressions of tissue inhibitors of metalloproteinases (tissue inhibitor of metalloproteinases-1/tissue inhibitor of metalloproteinases-2) and apoptosis (cleaved-Caspase3/cleaved-poly(ADP-ribose) polymerase) displayed an opposite pattern of AAA diameter among the groups (all p < 0.0001). The results of the present study support that triple therapy with DAPA + Entresto +..."

Journal • Preclinical • Cardiovascular • Immunology • Inflammation • Oncology • CASP3 • CD4 • IL6 • MMP2 • MMP9 • SMAD4 • TIMP1 • TNFA

Sacubitril/Valsartan in Patients with HFrEF Undergoing Maintenance Hemodialysis, Evidence of Cardiac Reverse Remodeling During 12-Month Follow-Up: Case Series. (PubMed, Reports (MDPI)) - "Blood pressure improved, serum potassium remained stable at 4.95 mmol/L, and no severe hyperkalemia, intradialytic hypotension, post-dialysis hypotension, or heart failure-related hospitalization occurred; In this case series, SV was associated with improved cardiac function, reverse remodeling, pulmonary pressure reduction, and an acceptable safety profile in patients with HFrEF undergoing MHD. These findings suggest a potential therapeutic role for SV in selected dialysis patients and support further investigation."

Journal • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Heart Failure • Hypotension • Nephrology • Renal Disease

The hemodynamic effects of sacubitril/valsartan in the first 24 h of initiation in pediatric cardiac intensive care unit patients: insights using high-fidelity data. (PubMed, Pediatr Cardiol) - "Linear mixed effects models were used to estimate post-initiation trends in absolute units from 2 to 24 h, accounting for repeated measures within patients and adjusting for age, ventricular assist device status, milrinone exposure, and circulatory physiology. Sacubitril/valsartan initiation in critically ill children is associated with coordinated changes in arterial, venous, and tissue-level physiology consistent with improved systemic oxygen delivery. The response appears continuous, with variability in magnitude across patients rather than discrete phenotypes."

Journal • Critical care • Pediatrics

Long-Term Renal Function and Clinical Outcomes of Sacubitril/Valsartan in HFrEF and Stage 3-4 Chronic Kidney Disease: A 24-Month Single-Centre Cohort. (PubMed, Clin Cardiol) - "In this single-arm cohort of HFrEF with stage 3-4 CKD, S/V was generally well tolerated, with stable renal function and low event rates over 24 months. These descriptive, hypothesis-generating findings cannot establish comparative benefit and require confirmation in controlled studies."

Clinical data • Journal • Retrospective data • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Heart Failure • Nephrology • Renal Disease

Glucagon-like Peptide-1 Metabolism and Acute Neprilysin Inhibition (clinicaltrials.gov) - P3 | N=0 | Withdrawn | Sponsor: University of Pennsylvania | N=25 ➔ 0 | Suspended ➔ Withdrawn

Enrollment change • Trial withdrawal • Cardiovascular • Congestive Heart Failure • Hypertension • Metabolic Disorders • Type 2 Diabetes Mellitus

Effect of Sacubitril/Valsartan versus Angiotensin Receptor Blocker or Calcium Channel Blockers on Ambulatory Blood Pressure and Safety in Hypertensive Patients: A Meta-Analysis of Randomized Controlled Trials. (PubMed, J Cardiovasc Pharmacol) - "Sensitivity analyses confirmed robust results with no significant publication bias. In conclusion, sacubitril/valsartan effectively improves multiple ambulatory blood pressure parameters with a favorable safety profile, supporting its rational use in hypertensive patients."

Journal • Retrospective data • Cardiovascular • Hypertension

Estimating the Benefits of the Comprehensive Disease-modifying Pharmacological Treatment in Patients with Heart Failure. (PubMed, Card Fail Rev) - "The numbers needed to treat per year for the primary outcome, cardiovascular death and first heart failure hospitalisation were 10, 23 and 15, respectively. Our findings support the potential benefit of comprehensive therapy, with the incremental role of vericiguat likely greatest in higher-risk patients or those with recent worsening heart failure."

Journal • Review • Cardiovascular • Congestive Heart Failure • Heart Failure

Long-Term Control of Refractory Cardiogenic Pleural Effusion in a Cat Treated with Sacubitril/Valsartan and Hydrochlorothiazide: A Case Report. (PubMed, Animals (Basel)) - "Hydrochlorothiazide is a thiazide diuretic that acts at a more distal segment of the nephron than furosemide...Despite conventional treatment, which included pimobendan, torasemide, and antithrombotic medications, the cat experienced multiple episodes of pleural effusion over the following months, requiring repeated thoracocentesis...Nonetheless, the duration and completeness of the response observed here warrant prospective evaluation of combination of ARNI therapy and hydrochlorothiazide in cats with refractory congestive heart failure. Further studies are needed to assess the safety and effectiveness of this approach in feline cardiomyopathy."

Journal • Pleural effusion • Atrial Fibrillation • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Fibrosis • Heart Failure • Respiratory Diseases

Sacubitril/valsartan and cardiac injury/stress and systemic inflammatory biomarkers in acute heart failure: a prespecified secondary analysis of the PREMIER study. (PubMed, Eur Heart J Cardiovasc Pharmacother) - "In haemodynamically stabilised patients hospitalised for AHF, no differential effects of Sac/Val versus continued ACEI/ARB therapy on cardiac injury/stress and systemic inflammatory biomarkers were demonstrated over 8 weeks. These findings do not support a broad biomarker-defined anti-inflammatory or cardioprotective effect of Sac/Val in this setting."

Biomarker • Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Inflammation • CRP • GDF15

Effect of Sacubitril-Valsartan on Estimated Pulmonary Artery Systolic Pressure in Patients With Heart Failure With Reduced Ejection Fraction Heart Failure (clinicaltrials.gov) - P1 | N=59 | Completed | Sponsor: Aswan University

New P1 trial • Cardiovascular • Congestive Heart Failure • Heart Failure

Early in-hospital initiation of dapagliflozin versus empagliflozin in acute heart failure: impact on in-hospital survival and safety (ESC 2026) - "Low event rates were observed in patients receiving combined SGLT2 inhibitor and sacubitril/valsartan therapy. Conclusion Early initiation of dapagliflozin and empagliflozin was associated with comparable overall survival and favourable safety profiles. Subgroup findings suggest differential benefits according to ventricular function and renal status, supporting early SGLT2 inhibitor use in acute heart failure."

Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypotension

Non-ischemic Dilated Cardiomyopathy In A 42-year-old The Malignant Phenotype And The Role Of Des Gene Analysis (HFSA 2026) - "Despite optimization on quadruple goal-directed medical therapy (GDMT)—including sacubitril/valsartan, carvedilol, spironolactone, and dapagliflozin, the patient's structural and electrical instability persisted.Investigations and Coronary angiography confirmed normal coronary arteries, and a comprehensive toxicology workup was negative. This case highlights the necessity of early geneticist involvement and testing in young patients with unexplained HFrEF, particularly when a malignant phenotype (concomitant stroke and arrhythmia) is present. Beyond confirming a structural etiology, genetic identification shifts management toward early heart transplant evaluation and mandates life-saving cascade screening for family members. Early identification allows for pre-symptomatic monitoring and intervention in relatives at risk for sudden cardiac death, effectively transforming a diagnostic mystery into a proactive, family-centered prevention strategy."

Cardiomyopathy • Cardiovascular • CNS Disorders • Congestive Heart Failure • Heart Failure • Ventricular Tachycardia

Sacubitril/Valsartan Is Associated With Improved Survival In Continuous-Flow Left Ventricular Assist Device Recipients [Poster no. 678] (HFSA 2026) - No abstract available

Cardiovascular

Early Initiation Of Sacubitril/valsartan In Acute Decompensated Heart Failure: A Systematic Review And Meta-analysis Of Randomized Controlled Trials. [Poster no. 655] (HFSA 2026) - No abstract available

Retrospective data • Review • Cardiovascular • Congestive Heart Failure • Heart Failure

Early Initiation Of Sacubitril/valsartan In Acute Or Worsening Heart Failure: A Systematic Review And Stratified Meta-analysis [Poster no. 488] (HFSA 2026) - No abstract available

Retrospective data • Review • Cardiovascular • Congestive Heart Failure • Heart Failure

Tolerability Of Sacubitril/Valsartan In Patients With Advanced Heart Failure With Reduced Ejection Fraction: Insights From LIFE-HF [Poster no. 422] (HFSA 2026) - No abstract available

Clinical • Metastases • Cardiovascular • Congestive Heart Failure • Heart Failure

Sacubitril Valsartan Versus Mineralocorticoid Receptor Antagonists For Heart Failure Readmission Risk Across All Subtypes [Poster no. 171] (HFSA 2026) - No abstract available

Cardiovascular • Congestive Heart Failure • Heart Failure

Effects Of Sacubitril/valsartan On Sexual/intimate Relationships: The PARADIGM-HF And PARAGON-HF Trials [Poster no. 167] (HFSA 2026) - No abstract available

A Randomized Trial of Sacubitril/Valsartan versus Enalapril in Chronic Chagas Cardiomyopathy with Reduced Ejection Fraction: Results of the ANSWER-HF Biomarker Subanalysis (AHA 2026) - "Abstract is embargoed at this time."

Biomarker • Clinical • Cardiomyopathy • Cardiovascular

Effect of sacubitril/valsartan on serum uric acid and blood pressure in patients with hypertension and asymptomatic hyperuricemia: A randomized clinical trial. (PubMed, Hypertens Res) - P=N/A | "Trial Registration Chinese Clinical Trial Registry: ChiCTR2100050320 ( https://www.chictr.org.cn ). Date of Registration: September 1, 2021."

Clinical • Journal • Cardiovascular • Hypertension

Pharmacotherapy of heart failure: Impact of the 2021 guideline update on guideline-directed medical therapy assessed using a Japanese employee health insurance claims database. (PubMed, Int J Clin Pharmacol Ther) - "The 2021 guideline update was associated with increased use of sacubitril/valsartan and dapagliflozin, resulting in greater overall GDMT intensity. However, these findings are limited to data from 2021, and further long-term studies are needed to evaluate trends in GDMT utilization."

Journal • Reimbursement • US reimbursement • Cardiovascular • Congestive Heart Failure • Heart Failure

Blood pressure in haemodialysis: measurement, volume control and drug selection. (PubMed, J Nephrol) - "Sacubitril/valsartan is biologically plausible when hypertension coexists with heart failure with reduced ejection fraction, left ventricular dysfunction, recurrent congestion, or high natriuretic peptide burden. However, it should be framed as a promising but not yet established selective option rather than routine escalation therapy."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension • Hypotension

Sacubitril/Valsartan: Breaking barriers in uterine adhesion and boosting pregnancy outcomes by suppressing inflammation and fibrosis. (PubMed, Iran J Basic Med Sci) - "Sac/Val enhances regeneration of endometrium and pregnancy outcomes in a rat model of IUA, primarily through suppression of inflammation and fibrosis. Further preclinical and clinical studies are needed to determine the protective functions of Sac/Val for IUA treatment."

Journal • Fibrosis • Immunology • Infertility • Inflammation • Sexual Disorders